Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.08.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Seung Hyun Jang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Kor…. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, KCNQ Potassium Channels, Hearing Loss, Sensorineural. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Ministry of Health and Welfare, Ministry of Science and ICT, South Korea, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Hearing loss is the most common sensory disorder, with a substantial proportion caused by genetic mutations. KCNQ4, a voltage-gated potassium channel highly expressed in cochlear outer hair cells, is a common genetic etiology implicated in autosomal dominant progressive hearing loss (DFNA2). The dominant-negative KCNQ4 p.W276S (c.827G>C) mutation represents a mutational hotspot in DFNA2, yet no effective treatments exist. Here, we developed allele-preferential antisense oligonucleotides (ASOs) targeting this dominant-negative KCNQ4 mutation. In a systemic in vitro screen, ASO-123 demonstrated a knockdown of mutant Kcnq4 while preserving wild-type transcripts. In a Kcnq4 p.W277S knockin mouse model mimicking DFNA2, ASO-123 preferentially suppressed mutant transcripts, attenuated progressive hearing loss, and improved outer hair cell survival while enhancing their electrophysiologic function. Comprehensive transcriptomic analyses further validated the efficacy of ASO-123. Thus, our findings establish ASO-based therapy as a promising strategy for treating hereditary hearing loss caused by dominant-negative KCNQ4 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Won-Sang Lee Institute for Hearing Loss, Seoul, Republic of Korea.
- Won-Sang Lee Institute for Hearing Loss, Seoul, Republic of Korea; Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Qmine, Seoul, Republic of Korea.
- Won-Sang Lee Institute for Hearing Loss, Seoul, Republic of Korea; Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Anatomy, Brain Korea 21 Project for Me…
- Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Won-Sang Lee Institute for Hearing Loss, Seoul, Republic of Korea.…
Förderung
- Korea Ministry of Health and Welfare
- Ministry of Science and ICT, South Korea
- Korea Health Industry Development Institute
- National Research Council of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Jang, S. H., Roh, J. W., Oh, K. S., Joo, S. Y., Kim, J. A., Kim, S. J., Choi, J. Y., Jung, J., Kim, Y., Bok, J., & Gee, H. Y. (2025). Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.08.044
Vancouver
Jang SH, Roh JW, Oh KS, Joo SY, Kim JA, Kim SJ, et al. Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.08.044
BibTeX
@article{Jang2025,
author = {Jang, Seung Hyun and Roh, Jae Won and Oh, Kyung Seok and Joo, Sun Young and Kim, Jung Ah and Kim, Se Jin and Choi, Jae Young and Jung, Jinsei and Kim, Yeonjoon and Bok, Jinwoong and Gee, Heon Yung},
title = {Antisense oligonucleotide therapy mitigates autosomal dominant progressive hearing loss in a murine model of human DFNA2},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.08.044}
}
EUVIMED